The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Current Opinions on the Radioiodine Treatment of Graves' Hyperthyroidism

Graves병 갑상선 기능항진증에서 방사성 옥소 치료의 지견

  • Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
  • 이상우 (경북대학교의과대학 핵의학교실) ;
  • 이재태 (경북대학교의과대학 핵의학교실)
  • Published : 2003.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Radioactive iodine therapy using I-131 for hyperthyroidism has been used for more than 50 years, and generally considered safe and devoid of major side effects. Appropriate patient selection criteria and clinical judgement concerning patient preparation should be employed for its optimal use. It has not been possible to resolve the trade-off between efficient definite cure of hyperthyroidism and the high incidence of post-therapy hypothyroidism. The dose of the I-131 needed to maintain euthyroid state remains an area of uncertainity and debate. Early side effects are uncommon and readily managable. Other than the need for long-term monitoring and, in most cases, lifelong thyroid hormone treatment for late adverse consequences of this treatment remains only conjectural. We have reviewed general principles and recent advances in radioiodine treatment for Graves' hyperthyroidism, specially regarding to several controversies.

Keywords

References

  1. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8 https://doi.org/10.1056/NEJM199406163302407
  2. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35 https://doi.org/10.1089/thy.1991.1.129
  3. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-24 https://doi.org/10.1210/jcem-70-6-1518
  4. 조보연, 고창순. 한국에서 그레이브스병의 진단과 치 료 현황. -설문조사 분석 및 유럽, 미국, 일본과의 비 교. 대한내분비학회지 1992;7:216-27
  5. Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med 1996;26 :155-64 https://doi.org/10.1016/S0001-2998(96)80020-1
  6. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974;38:976-98 https://doi.org/10.1210/jcem-38-6-976
  7. Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine($^131$I) for hyperthyroidism. N Engl J Med 1975;292:167-71 https://doi.org/10.1056/NEJM197501232920401
  8. Kaplan MM, Meier DA, Dwaorkin HJ. Treatment of hyperthyroidism with radioactive iodine. Endocrionol Metab Clin North Am 1998;27:205-22 https://doi.org/10.1016/S0889-8529(05)70307-8
  9. Hayek A, Chapman EM, Crawford JD. Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. N Engl J Med 1970;283:949-53 https://doi.org/10.1056/NEJM197010292831802
  10. Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, et al. Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1-4
  11. Bae SK. Radioiodine therapy of thyroid disease. Korean J Nucl Med 2001;35:P11-8
  12. Gittoes NJ, Franklyn JA. Hyperthyroidism. Current treatment guidelines. Drugs 1998;55:543-53 https://doi.org/10.2165/00003495-199855040-00005
  13. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-A prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986-93
  14. Lind P. Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med 2002;29:S453-7 https://doi.org/10.1007/s00259-002-0831-4
  15. Wang CY, Chang TJ, Chang TC, Hsiao YL, Chen MH, Huang SH. Thyroidectomy or radioiodine? The value of ultrasonography and cytology in the assessment of nodular lesions in Graves' hyperthyroidism. Am Surg 2001;67:721-6
  16. Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976;17:146-9
  17. Meier DA, Brill DR, Becker DV, Clarke S, Silberstein EB, Royal HD, Balon HR. Procedure guideline for therapy of thyroid disease with iodine-131. J Nucl Med 2002;43:856-61
  18. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-- prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611-7 https://doi.org/10.1210/jc.86.8.3611
  19. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves ' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-42 https://doi.org/10.1210/jc.85.3.1038
  20. Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87: 1073-7 https://doi.org/10.1210/jc.87.3.1073
  21. 이광우, 손현식, 한제호, 유순집, 윤건호, 강무일, 홍 관수, 차봉연, 손호영, 강성구. 그레이브스 갑상선기 능항진증 환자의 방사성옥소 치료에 있어서 10 mCi 투여군과 일반적 계산용량 투여군의 3년간 추적결과. 대한내분비학회지 1992;7;358-63
  22. Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol 1995;43:325-9
  23. Kok SW, Smit JW, de Craen AJ, Goslings BM, van Eck-Smit BL, Romijn JA: Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nucl Med Commun 2000;21:1071-8 https://doi.org/10.1097/00006231-200011000-00014
  24. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003;88:978-83 https://doi.org/10.1210/jc.2002-020805
  25. Nordyke RA, Gilbert FI Jr. Optimal I-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991;32;411-6
  26. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001;28:1489-95 https://doi.org/10.1007/s002590100621
  27. Willemsen UF, Knesewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease. Eur J Nucl Med 199;20:1051-5
  28. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002;29:1118-24 https://doi.org/10.1007/s00259-002-0877-3
  29. Rini JN, Vallabhajosula S, Zanzonico P, Hurley JR, Becker DV, Goldsmith SJ. Thyroid uptake of liquid versus capsule $^1$I tracers in hyperthyroid patients treated with liquid $^1$I. Thyroid 1999;9:347-52 https://doi.org/10.1089/thy.1999.9.347
  30. Wesche MF, Tiel-van Buul MM, Smits NJ, Wiersinga WM. Ultrasonographic versus scintigraphic measurement of thyroid volume in patients referred for $^131$I therapy. Nucl Med Commun 1998;19:341-6 https://doi.org/10.1097/00006231-199804000-00008
  31. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism. significance of effective half-life measurements. J Nucl Med 1996;37:228-32
  32. Moka D, Voth E, Schicha H. Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy. Nuklearmedizin 1997;36:87-92
  33. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999;84:1229-33 https://doi.org/10.1210/jc.84.4.1229
  34. Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years' experience with Graves' disease. Arch Intern Med 1979;139:651-3 https://doi.org/10.1001/archinte.139.6.651
  35. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995;5:243-7 https://doi.org/10.1089/thy.1995.5.243
  36. Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy. relation to opthalmopathy, the possible redioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrionol 2002;147:1-11 https://doi.org/10.1530/eje.0.1470001
  37. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism. one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86:3488-93 https://doi.org/10.1210/jc.86.8.3488
  38. Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol 1997;47:425-30 https://doi.org/10.1046/j.1365-2265.1997.2741075.x
  39. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83: 685-7 https://doi.org/10.1210/jc.83.2.685
  40. Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 2002;147:1-11 https://doi.org/10.1530/eje.0.1470001
  41. Bogazzi F, Bartalena L, Brogioni S, Scarello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1999;84:499-503 https://doi.org/10.1210/jc.84.2.499
  42. Tepmongkol S: Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide. a prospective randomised control study. Eur J Nucl Med 2002;29:1307-10 https://doi.org/10.1007/s00259-002-0893-3
  43. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med 2002;29:S486-91 https://doi.org/10.1007/s00259-001-0717-x
  44. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 2002;12:399-405 https://doi.org/10.1089/105072502760043486
  45. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990;150:1098-101 https://doi.org/10.1001/archinte.150.5.1098
  46. ${\sim}$Tallstedt L, Lundell G, Taube A. Graves' ophthalmopathy and tobacco smoking. Acta Endocrinol 1993;129:147-50
  47. Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Laurberg P, Mosekilde L. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid 2002;12:69-75 https://doi.org/10.1089/105072502753451995
  48. Bartalena L, Pinchera A, Marcocci C: Management of Graves' ophthalmopathy. reality and perspectives. Endocrine Reviews 2000;21:168-99 https://doi.org/10.1210/er.21.2.168
  49. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol 1999;51:503-8 https://doi.org/10.1046/j.1365-2265.1999.00843.x
  50. Pinchera A, Bartalena L, Marcocci C. Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but.. J Clin Endocrinol Metab 1995;80:342-5
  51. Gorman CA. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 1995;80:340-2 https://doi.org/10.1210/jcem.80.2.7852485
  52. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8 https://doi.org/10.1056/NEJM199206253262603
  53. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130: 494-7
  54. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8 https://doi.org/10.1056/NEJM199801083380201
  55. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcome in Graves opthalmopathy. Ann Intern Med 1998;129:632-5 https://doi.org/10.7326/0003-4819-129-8-199810150-00010
  56. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997;7:259-64 https://doi.org/10.1089/thy.1997.7.259
  57. Weetman AP, Harrison BJ. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998;21:472-5
  58. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol 1991;34:71-6 https://doi.org/10.1111/j.1365-2265.1991.tb01738.x
  59. Hennemann G, Krenning EP, Sankaranarayanan K. Place of radioactive iodine in treatment of thyrotoxicosis. Lancet 1986;1:1369-72
  60. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol 2001;55:233-9 https://doi.org/10.1046/j.1365-2265.2001.01329.x
  61. Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986;105:900-5 https://doi.org/10.7326/0003-4819-105-6-900
  62. Kalinyak JE, McDougall IR. Editorial. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab, 2003;88:975-7
  63. Nygaard B, Faber J, Veje A, Hegedus L, Hanssen JM. Relation between thyroid stimulating immunoglobulin and transient thyrotoxicosis in 4 patients treated with I-131 for non-toxic multinodular goiter. Eur J Endocrinol 1994;130;7
  64. Weiss M, Gorges R, Hirsch F, Bader J, Tatsch K, Hahn K. Immunogenic hyperthyroidism following iodine-131 therapy of non-immunogenic, autonomous thyroid nodules: results of a multicenter evaluation. Med Klin 1999;94:239-43 https://doi.org/10.1007/BF03045047
  65. 배진호, 정신영, 안병철, 이재태, 이규보. I-131 치료 에 의한 Graves병의 악화. 대한핵의학회지 2003;5: 68p
  66. Ron E, Doody MM, Becker DV. Brill AB, Curtis RE, Goldman MB, Benjamin SH, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice Jr JD. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280:347-55 https://doi.org/10.1001/jama.280.4.347